Impact BioMedical, Inc. - IBO Net Assets per Single Share

Impact BioMedical Inc (IBO) is implementing a patent monetization strategy through licensing agreements with industry behemoths. Growth is driven by the market launch of the 3F repellent and the sale of intellectual property rights. The company is developing antibacterial solutions to combat fungal resistance. The net book value per share reflects the organization's current capital, with the indicator standing at 1.27.

Accounting Value of a Share: impactbiomedinc.com (IBO) for 09/17/2024 - 10/27/2026

impactbiomedinc.com - analytical breakdowns and key metrics (IBO)

- price and consensus price forecast:
Price Chart Impact BioMedical Inc|IBO - Average Forecast Price
- market capitalization data:
Market Value Impact BioMedical Inc|IBO - Full Business Value
- book capitalization data:
Book Value per Share Impact BioMedical|IBO - Accounting Value of Company|Market Capitalization to Book Value Ratio impactbiomedinc.com|IBO - Company Total Assets
- debt and liquidity data:
Debt to Equity Impact BioMedical Inc|IBO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Impact BioMedical|IBO - Company Total Debt|Debts to Book Capitalization Impact BioMedical Inc
Analysis of all company metrics:Impact BioMedical Inc (IBO)

The specifics of Impact BioMedical Inc. (IBO) biotechnological developments are characterized by low cyclicality and long-term licensing demand, which makes the company dependent on venture financing. This metric reflects the residual value of net assets after all liabilities are settled, allowing the investor to assess the business's internal resilience to macro shocks and the risk of write-downs through the dynamics of equity per share.

Competitor analysis

HLN (Haleon Group) - Net Assets per Single Share|KVUE: Net Asset Value per Share|Net Assets per Single Share Verona Pharma plc (VRNA)|jyongbio.com (MENS) - Share Book Value|LGND - Book Value per Share|Accounting Value of a Share Amneal Pharmaceuticals, Inc.|Book Value per Share PRGO|Book Value per Share ALVO (Alvotech Biopharmaceuticals)|Net Assets per Single Share Liquidia Corporation|glpg.com - Accounting Value of a Share|ANIP: Net Assets per Single Share|MNKD - Accounting Value per Share|AMPH: Book Value per Share|Book Value per Share Pacira Corp|SPRY - Accounting Value per Share|Accounting Value of a Share TBPH|Aquestive Therapeutics, Inc. - Net Assets per Single Share|Net Asset Value per Share scpharmaceuticals.com SCPH|Accounting Value per Share Tectonic Therapeutic (TECX)|Book Price of a Share Tonix Pharmaceuticals Holding TNXP|Book Value per Share SXT China (SXTC)|EPRX - Accounting Value of a Share|Book Value per Share BHST|EXOZ (Invizyne Technologies) - Net Asset Value per Share|ORMP - Net Assets per Single Share|Accounting Value of a Share Entera Bio Corp|HYFT (MindWalk Holdings) - Book Value per Share|Net Assets per Share ABVC (abvcpharma.com)|Cumberland Pharmaceuticals Inc. - Net Assets per Single Share|Quantum BioPharma Ltd. - Accounting Value per Share|Net Assets per Single Share FibroGen Corp|TELO - Share Book Value|RANI: Book Value per Share|Synergy CHC (SNYR) - Book Value per Share|Book Value per Share RLYB|Accounting Value per Share Lexaria (LEXX)|Accounting Value per Share Pulmatrix Corp|Book Price of a Share ftzy.com.cn PTHL|Accounting Value per Share Aptorum Group|Accounting Value of a Share lyratherapeutics.com LYRA|TNFA - Book Value per Share|YCBD - Net Assets per Single Share|PainReform Limited - Book Value per Share|CYTO (Altamira Therapeutics Ltd.) - Net Assets per Share|Net Assets per Single Share LIPO (Lipella Pharmaceuticals)|Net Asset Value per Share OPTN|Net Assets per Single Share PIRS (Pieris Pharmaceuticals, Inc.)|Accounting Value per Share Procaps Group (PROC)|PTPI: Book Value per Share|Net Asset Value per Share Qilian International Corp QLI|Acelyrin, Inc. (SLRN) - Book Value per Share|TFFP - Equity per Share